Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Discontinuation of therapy Clear all
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 21, 2026, 7:14 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

NCT05427812
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

NCT04172675
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
22
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer

NCT02328105
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Abraxane
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Impact of Evolocumab in Cardiac Transplant Patients With CAV

NCT03944577
View directory record Official record
Conditions
Heart Transplant
Interventions
Evolocumab
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 21, 2026, 7:14 AM EDT
Terminated Not applicable Interventional Results available

Effect of Upper Airway Stimulation on Vascular Function in Obstructive Sleep Apnea

NCT03051165
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Hypoglossal Nerve Stimulation Treatment Withdrawal
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 21, 2026, 7:14 AM EDT
Terminated Phase 3 Interventional Results available

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study

NCT03563053
View directory record Official record
Conditions
Ataxia Telangiectasia, Genetic Syndrome
Interventions
EryDex System
Combination Product
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 21, 2026, 7:14 AM EDT
Terminated Phase 3 Interventional

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

NCT05329545
View directory record Official record
Conditions
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Upifitimab rilsodotin, Placebo
Drug · Other
Lead sponsor
Mersana Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

NCT07310901
View directory record Official record
Conditions
Obese But Otherwise Healthy Participants
Interventions
CRB-913, Placebo
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Chandler, Arizona • Rancho Cucamonga, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

NCT00983619
View directory record Official record
Conditions
B-cell Malignancies, Cancer
Interventions
MEDI-551, Rituximab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 21, 2026, 7:14 AM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

NCT04912856
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 21, 2026, 7:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

NCT03371381
View directory record Official record
Conditions
Adenocarcinoma of Lung
Interventions
JNJ-64041757, Nivolumab
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Baltimore, Maryland • Nashville, Tennessee • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 7:14 AM EDT
Withdrawn Not applicable Interventional

The Biophysical Impact of Transcutaneous Spinal Cord Stimulation Within a Single Session

NCT03046875
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Transcutaneous Spinal Cord Stimulation, Sham stimulation
Other
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 21, 2026, 7:14 AM EDT
Terminated No phase listed Observational

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

NCT01465516
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Boceprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

NCT00688909
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older · Female only
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
48
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Grass Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

NCT01916447
View directory record Official record
Conditions
Advanced Gastrointestinal Tumors
Interventions
TAS-102, CPT-11, Bevacizumab
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Not applicable Interventional

Focused Incentive Spirometry Monitoring to Reduce Postoperative Oxygen Therapy and Respiratory Complications After Bariatric Surgery

NCT03010852
View directory record Official record
Conditions
Respiratory Complication
Interventions
Focused incentive spirometer education and monitoring
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 21, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072630
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 21, 2026, 7:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sacituzumab Govitecan-hziy (SG), Docetaxel
Biological · Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
37
States / cities
Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 21, 2026, 7:14 AM EDT
Recruiting Phase 2 Interventional

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

NCT06458036
View directory record Official record
Conditions
Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Interventions
Selpercatinib Monotherapy, 131I Therapy
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 25 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
5
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Memphis, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 7:14 AM EDT
Recruiting Not applicable Interventional

Bilevel Positive Airway Pressure (BPAP) for Severe Asthma

NCT07582211
View directory record Official record
Conditions
Pediatric Asthma, Acute Asthma, BiPAP, Non-invasive Positive Pressure Ventilation
Interventions
Bilevel positive airway pressure ventilation
Device
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 21, 2026, 7:14 AM EDT